By Connor Hart
Vaxart appointed Jeroen Grasman as its chief financial officer, effective May 19.
Grasman will succeed Phillip Lee, who is resigning from the top finance position for personal reasons, the clinical-stage biotechnology company said Tuesday.
Lee will remain with the company as a non-executive employee through June 1 in order to assist with the transition.
Grasman has more than 20 years of financial leadership experience in the biotechnology industry, Vaxart said. He most recently served as CFO of AltruBio, a private clinical-stage biotech company. Prior, he held leadership roles at PACT Pharma and Intarcia Therapeutics.
Vaxart disclosed the CFO succession as it posted a net loss of $15.6 million, or 7 cents a share in the first quarter, compared with a loss of $24.4 million, or 14 cents a share, a year earlier.
Revenue increased to $20.9 million from $2.2 million.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
May 13, 2025 16:21 ET (20:21 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。